Identifying High-Risk Patients for Non-Valvular Atrial Fibrillation in Community Practices
Premiere Date: Monday, November 19, 2018
This activity offers CE credit for:
- Physicians (CME)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date: Monday, November 18, 2019
|Christopher P. Cannon, MD (Moderator)
Director, Education, Cardiovascular Medicine Innovation
Cardiovascular Division, Brigham and Women?s Hospital
Professor of Medicine, Harvard Medical School
|Deepak L. Bhatt, MD, MPH, , FACC, FAHA, FSCAI, FESC
Executive Director of Interventional Cardiovascular Programs
Brigham and Women’s Hospital Heart & Vascular Center
Professor of Medicine, Harvard Medical School
|Elaine M. Hylek, MD, MPH
Director, Thrombosis and Anticoagulation Service
Boston Medical Center
Professor of Medicine
Boston University School of Medicine
Statement of Need
Atrial fibrillation (AF) is the most common arrhythmia in clinical practice and a leading cause of morbidity and mortality. Due to the increasing age of the U.S. population, the “perceived” incidence of AF is increasing; however, patients may not notice symptoms that warrant care-seeking. This leads to physicians not having an index of suspicion relative to those at high risk for AF. Increased screening and use of anticoagulation treatment can help high-risk patients and likely decrease the number of patients who are not diagnosed with AF until they have had an AF-related stroke.
In this CME Outfitters On Demand, expert faculty address the impact of underdiagnosed NVAF and the benefits and uses of screening tools and appropriate implementation of oral anticoagulant therapy.
At the end of this CE activity, participants should be able to:
- Examine the significance of identifying patients at high risk for NVAF in the primary care setting who might benefit from anticoagulant therapy.
Supported by an educational grant from the Bristol-Myers Squibb and Pfizer Alliance.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse Practitioners can also apply for credit through their state boards.
Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Cannon reports that he receives research grants from Amgen Inc.; Boehringer-Ingelheim (BI); Bristol-Myers Squibb Company (BMS); Daiichi Sankyo; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc. He is a consultant for Alnylam Pharmaceuticals, Inc.; Amarin Corporation; Amgen Inc.; Boehringer-Ingelheim (BI); Bristol-Myers Squibb Company (BMS); Eisai Inc.; Janssen Pharmaceuticals, Inc.; Kowa Pharmaceuticals America, Inc.; Merck & Co., Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; sanofi-aventis U.S. LLC.
Dr. Bhatt reports that he receives research grants from Abbott; Amarin Corporation; Amgen Inc.; Astra Zeneca; Bayer Corporation; Boehringer Ingelheim; Bristol-Myers Squibb Company; Chiesi USA, Inc.; Eisai Inc.; Ethicon USA, LLC; Forest Laboratories; Idorsia Pharmaceuticals Ltd; Ironwood Pharmaceuticals, Inc.; Ischemix; Lilly USA; Medtronic; PhaseBio Pharmaceuticals, Inc.; Pfizer Inc.; Regeneron; Roche; sanofi-aventis U.S. LLC; Synaptic; and The Medicines Company.
Dr. Hylek reports that she received a research grant from Janssen Pharmaceuticals, Inc. Speakers sympoisa for Boehringer Ingelheim; Bristol-Myers Squibb Company; Medtronic; Pfizer Inc. She is consultant for Bristol-Myers Squibb Company; Janssen Pharmaceuticals, Inc.; Medtronic
Dr. Helfand (peer reviewer) has no disclosures to report.
Ms. Ochoa (peer reviewer) has no disclosures to report.
Kashemi D. Rorie, PHD (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.